Artelo Biosciences, Inc.
ARTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $6 | $4 | $3 |
| G&A Expenses | $4 | $4 | $6 | $5 |
| SG&A Expenses | $4 | $4 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $10 | $10 | $7 |
| Operating Income | -$10 | -$10 | -$10 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $0 | $0 |
| Pre-Tax Income | -$10 | -$9 | -$10 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$9 | -$10 | -$7 |
| % Margin | – | – | – | – |
| EPS | -3.05 | -3.14 | -3.49 | -5.97 |
| % Growth | 2.9% | 10% | 41.5% | – |
| EPS Diluted | -3.05 | -3.14 | -3.49 | -5.97 |
| Weighted Avg Shares Out | 3 | 3 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 3 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$10 | -$10 | -$7 |
| % Margin | – | – | – | – |